Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024.pdf (PDF, 551Kb)
Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76), June 2023.pdf (PDF, 525Kb)
Stereotactic Ablative Radiotherapy (SABR) for people aged 18 years old and above with primary kidney cancer, Commissioning Policy (CP279), June 2024.pdf (PDF, 512Kb)
Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215), October 2023.pdf (PDF, 353Kb)